Phase in Medical News

AspireHR Completes Phase 1 SAP HR Initiative for Shire Pharmaceuticals

AspireHR and Shire Pharmaceuticals complete Phase 1 of their shared SAP human resources initiative. Wayne, PA (PRWEB) August 7, 2009 -- AspireHR, an SAP HR software, consulting, and SaaS company, is proud to announce the successful Go-Live of Phase 1 of their SAP HR ini...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

EXTON, Pa., Aug. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that dosing has begun in the Phase 1 clinical trial for NTCD (non-toxigenic Clostridium difficile ), a novel treatment approach for preventing recurrent Clostridium difficile infections (...

Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer

HOUSTON, Aug. 6 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is be...

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

EMERYVILLE, Calif., August 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) today announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. In the trial, Bezielle showed an excellent sa...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 cli...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathw...

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment...

QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy

ANN ARBOR, Mich., July 29 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophe...

QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System

VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) ("QLT" or the "Company") today announced encouraging interim data from an ongoing Phase II clinical trial and a device study for the punctal plug delivery system. These studies are part of a development program that i...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 23, 2009 at 7:00 pm EDT (4:00 pm PDT). Members of Rigel's senior management team and the p...

Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study

DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY ) www.quigleyco.com , today announced the results from its Phase IIb double-blind, placebo-controlled, study of topical compound QR-333 for the tre...

AcelRx Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study

REDWOOD CITY, Calif., July 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01 Sufentanil NanoTab(TM) PCA System for management of acute pos...

US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

THE WOODLANDS, Texas, July 20 /PRNewswire/ -- US Oncology, Inc . today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in p...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

SAN DIEGO, July 20 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that all three remaining Phase 3 trials evaluating Contrave(R) (bupropion SR/naltrexone SR), its investigational drug for the treatment of obesity, met their ...

Reminder - Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Systemic Lupus Erythematosus

ROCKVILLE, Maryland July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) will host a conference call today at 8:15 AM Eastern to discuss the results from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly Ly...

A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits

VIENNA, July 15 /PRNewswire-USNewswire/ -- New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Asso...

Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome

NOVATO, Calif., July 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the ly...

Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment

LA JOLLA, Calif., July 8 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical company focused on developing non-invasive, topically administered products, today announced they have successfully completed the enrollment of patients in their ...

EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease

WATERTOWN, Mass., July 7 /PRNewswire/ -- WHAT: EnVivo Pharmaceuticals to share results from its Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. WHEN: Wednesday, July 15, 2009. ...

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3

Merrimack Pharmaceuticals' second of five oncology pipeline candidates, MM-111, a bispecific antibody, has entered clinical development. Preclinical studies have demonstrated that the bispecific approach shows antitumor activity in a wide range of tumor types. The current Phase 1/2 study will eva...

MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations

MDS Pharma Services to Focus on the Delivery of Early Stage Services - Discovery Through Phase IIa TORONTO, July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ ), a leading provider of products and services to the global life sciences markets, today announced that it has...

Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility - TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Pereg...

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases

Results Demonstrate Positive Proof of Mechanism SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. The interim resu...

Emory researchers announce Phase III study of progesterone for traumatic brain injury

Emory University officials this week announced the third phase of a groundbreaking study to evaluate the effectiveness of the hormone progesterone on acute traumatic-brain-injured patients. Backed by a grant from the National Institutes of Health (NIH), the Emory-led, multicenter, randomized, ...

Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients

ActoGeniX taps Biomodels CRO expertise in $1 billion market for cancer support care to relieve side effects of cancer treatments WATERTOWN, Mass., June 22 /PRNewswire/ -- Biomodels LLC, a preclinical research organization specializing in cancer support care, today announced that its customize...

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization

Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) announced today positive results from two global multi-center Phase III...

Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study

LA JOLLA, Calif., June 15 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical company focused on developing non-invasive, topically administered products, announced that they anticipate reporting top-line results from their current Phase 3...

FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer

BOSTON, June 15 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfus...

InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose th...

Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia

PALO ALTO, Calif., June 9 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented this week during the Associated Professional Sl...

Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada

VANCOUVER, June 9 /PRNewswire-FirstCall/ - Medifocus, Inc. (TSXV:MFS) is pleased to announce that it has been granted the Investigational Testing Authorization (ITA) from Health Canada's Medical Device Bureau (MDB) for initiating Medifocus' pivotal trial with the Microfocus APA 1000 Breast Thermot...

Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study

NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced results from the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The company expects to initiate the Ph...

Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack

- SYNCHRONY Study Published in The Lancet Supports Cardio-Protective Potential of Aleglitazar - NUTLEY, N.J., June 9 /PRNewswire/ -- Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients

- PSI-7851 was generally safe and well tolerated in Phase 1a single ascending dose trial - Further results from single ascending and multiple ascending dose trials are expected in second half 2009 PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) annou...

Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of as y...

Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis

- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis. The data were presented as part of the ...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

ProLindac Showing High DACH Platinum Activity; Drug Well Tolerated With No Signs of Acute Neurotoxicity DALLAS, June 1 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC . ( http://www.accesspharma.com ) (OTC Bulletin Board: ACCP), provided an update today on the progress ...

Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer

WAYNE, N.J. and EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar(R) (sorafenib) tablets...

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. Na...

MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa

Company to Divest Late Stage Operations, Signs Agreement to Sell Phase II-IV Operations to INC Research TORONTO, June 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ ), a leading provider of products and services to the global life sciences markets, today announced that i...